Alaunos Therapeutics, Inc. · NASDAQ:TCRT
Alaunos Therapeutics — Investor Presentation (September 2022)
23 slides from Alaunos Therapeutics's investor presentation, September 2022
Slide 1: Attacking Solid Tumors with Novel TCR-T Cell Therapies
Attacking Solid Tumors with Novel TCR-T Cell Therapies September 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will
Slide 3: Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors
Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors Vision 2022 – Execution Mindset, Delivering Results Phase 1/2 TCR-T Library Trial Enrolling; Confirmed Partial Response in First Patient Weaponizing the 1 (NSCLC); Now Treating at Dose Level 2 immune system with powerf
Slide 4: TCR-T Platform with Multiple Solid Tumor Programs in Pipeline
TCR-T Platform with Multiple Solid Tumor Programs in Pipeline PROGRAM TARGETS INDICATION DISCOVERY PRECLINICAL IND-ENABLING PHASE 1 Lung Colon/rectum Library TCR-T cell Therapy Endometrium KRAS, TP53 & EGFR Hotspot Mutations Pancreas (Company Sponsored at MDACC - NCT05194735) Ovary Bile Duct mbIL-15
Slide 5: TCR-T is Superior to Other Cell Therapy Approaches for Solid Tumors
TCR-T is Superior to Other Cell Therapy Approaches for Solid Tumors TCR-T CAR-T TIL Target Intracellular & Extracellular Antigens Proven Efficacy in Solid Tumors Defined Target Specificity Targets Somatic Neoantigens Established Transposon-based Gene Transfer 5 Table above not based on head-to-head
Slide 6: A Differentiated TCR-T Program Targeting Solid Tumors
A Differentiated TCR-T Program Targeting Solid Tumors Targeting Hotspot Sleeping Beauty hunTR™ Platform Mutations Technology (human neoantigen T cell Receptor) Hotspot mutations are Non-viral transposition ideal targets for technology has favorable Robust discovery engine defeating cancer safety pro
Slide 7: Our TCR-T Cell Platform Targets Solid Tumors in Large Patient Populations
Our TCR-T Cell Platform Targets Solid Tumors in Large Patient Populations with Unmet Clinical Need 2022 Incidence - USA • In the US, 92% of new cancer cases Lung 236,740 are solid tumors Colon and Rectum 151,030 • 4,804 patients are diagnosed every day with cancerous solid tumor Endometrial 65,950 •
Slide 8: KRAS, TP53, EGFR Mutations are Commonly Expressed in Targeted Indications
KRAS, TP53, EGFR Mutations are Commonly Expressed in Targeted Indications High frequency tumor targets, not expressed in normal tissues Killer TCR-T cells specific for the mutation without off-tumor toxicity Unmet clinical need for patients with solid tumors 8 Source: Catalogue of Somatic Mutations
Slide 9: TCRs Can Give Patients' T Cells a New Ability to Recognize and Kill Tumor Cells
TCRs Can Give Patients' T Cells a New Ability to Recognize and Kill Tumor Cells with Common Mutations 9
Slide 10: TCR Library Captures High Frequency Mutations and HLA Types
TCR Library Captures High Frequency Mutations and HLA Types • Common HLAs are represented in our TCR library • Certain mutations have more than one HLA restriction • As more TCRs are added to our library, the addressable patient market size will further increase 10
Slide 11: Non-viral Sleeping Beauty Platform for Manufacturing TCR-T Cells
Non-viral Sleeping Beauty Platform for Manufacturing TCR- T Cells without the Complexity of Gene Editing • Efficient integration without the complexity of gene editing or viral approaches • Rapid, cost-effective manufacturing • Flexible approach to add TCRs; attractive choice for library • Platform
Slide 12: TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells
TCR-T Cells Recognize KRAS, TP53, EGFR Mutations and Kill Solid Tumor Cells Powerful TCRs: Naturally-occurring, high avidity TCRs recognize low levels of neoantigens No off-target toxicity observed: Specificity for the mutation with negligible recognition of the wild type sequences Tumor killing: Re
Slide 13: Each Autologous TCR-T Cell Product is Manufactured with a Matched TCR
Each Autologous TCR-T Cell Product is Manufactured with a TCR Matched for the Patient’s Mutation and HLA Type Screening 1 Infusion 6 2 Selection of TCR from Library for Manufacturing 5 3 TCR Expression & Peripheral Blood Expansion Leukapheresis 4 Sleeping Beauty Transposition of TCR 13
Slide 14: Actively Enrolling First-in-Human TCR-T Clinical Trial with Innovative Library Approach
Actively Enrolling First-in-Human TCR-T Clinical Trial with Innovative Library Approach Trial enrolling patients where a TCR matching a neoantigen / HLA pairing Phase I Objectives: is available in our TCR-T library Define dose limiting toxicity Phase I is a prospective, open-label, dose-escalation s
Slide 15: Confirmed Partial Response in Patient #1 Following Treatment with Sleeping Beauty TCR-T Cells
Confirmed Partial Response in Patient #1 Following Treatment with Sleeping Beauty TCR-T Cells Patient #1 Indication Checkpoint inhibitor and chemotherapy refractory NSCLC TCR Library Match KRAS G12D mutation and HLA-A*11:01 Dose Level Treated at dose level 1 with 9 billion TCR-T cells Manageable saf
Slide 16: Patient #1: Complete Resolution of Right Lower Lobe Target Lesion
Patient #1: Complete Resolution of Right Lower Lobe Target Lesion Insert Image Here Insert Image Here Insert Image Here 0 6 12 Baseline Week 6 Week 12 1.3 cm 0.0 cm 0.0 cm 16 Note: Red circle represents target lesion
Slide 17: Patient #1: Reduction of Right Hilar Lymph Node
Patient #1: Reduction of Right Hilar Lymph Node 0 6 12 Baseline Week 6 Week 12 1.5 cm 1.1 cm 1.0 cm 17 Note: Red circle represents target lesion
Slide 18: Patient #1: TCR-T Cells Exhibited Rapid Expansion and Ongoing Persistence
Patient #1: TCR-T Cells Exhibited Rapid Expansion and Ongoing Persistence at Week 12 Circulating TCR-T Cells 1250 TCR-T Cells / μL Blood Day 4 Week 12 1000 TCR-T Cells/µL 1,038 134 750 TCR-T Copies/µg 5x105 2.5x104 500 % TCR-T+ of CD3+ 98.4% 22.5% 250 0 0 2 4 6 8 12 Weeks Post-Infusion 18
Slide 19: Promising Data Demonstrates Potential of TCR-T Cell Therapy in Solid Tumors
Promising Data Demonstrates Potential of TCR-T Cell Therapy in Solid Tumors Patient Dose (TCR-T Cells) Best Response Time on Trial 1 9 Billion Partial Response 5 months and ongoing 2 64 Billion Stable Disease 3 months • First report of successful TCR-T cell therapy using non-viral Sleeping Beauty sy
Slide 20: hunTR Program Rapidly Expands TCR Library Targeting Hotspot Mutations
hunTR™ Program Rapidly Expands TCR Library Targeting Hotspot Mutations Focus on neoantigens, particularly those arising from hotspot mutations Empirical screening of TCRs from CD4+ and CD8+ T cells directly from tumor High-throughput TCR screening 20
Slide 21: mbIL-15 Improves the Persistence and Anti-tumor Activity of TCR-T cells
mbIL-15 Improves the Persistence and Anti-tumor Activity of TCR-T cells in the Tumor Microenvironment (TME) Pro-survival signaling limits negative signals from the TME Stem-cell memory mbIL-15 TCR-T cells regenerate TCR-T cells Limit effects of HLA loss by supporting TILs and NK cells Potential for
Slide 22: Experienced Management Team
Experienced Management Team Kevin S. Boyle, Sr. Melinda Lackey Chief Executive Officer SVP Legal Drew Deniger, PhD Abhishek Srivastava, PhD Mike Wong VP Research & Development VP Research & Development VP Finance Melinda Lackey 22
Slide 23: Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors
Shareholder Value Creation: A Clinical Stage TCR-T Company Targeting Solid Tumors Vision 2022 – Execution Mindset, Delivering Results Phase 1/2 TCR-T Library Trial Enrolling; Confirmed Partial Response in First Patient Weaponizing the 1 (NSCLC); Now Treating at Dose Level 2 immune system with powerf
Alaunos Therapeutics — Investor Presentation (September 2022) on 6ix